Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Zenotech has two heads and gets behind as Daiichi Sankyo watches on

This article was originally published in Scrip

Executive Summary

All is not settled at the Indian biotech firm, Zenotech Laboratories, with its founder complaining that two heads are not better than one, and lamenting that Daiichi Sankyo, now in effect a majority shareholder in the company, has not been sufficiently involved in running it. Industry analysts are now becoming concerned that intra-management carping at Zenotech is causing the company to lose ground on its rivals.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC012898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel